The study conducted by the University Hospital, Grenoble, aims to explore TRP channels as potential therapeutic targets for Raynaud's phenomenon, a condition with limited treatment options. Given the prevalence of primary Raynaud's in 4-6% of the general population and the significant morbidity associated with secondary forms linked to systemic sclerosis, there is a substantial unmet medical need. The findings could pave the way for novel therapeutic interventions, potentially positioning TRP channel modulators as competitive alternatives to existing treatments, which currently offer modest efficacy. The market for Raynaud's treatments is relatively niche but could expand significantly if effective therapies are developed, especially for severe cases that lead to complications such as digital ulcers and amputations.